RSS-Feed abonnieren
DOI: 10.1055/a-1493-0683
Is there an HbA1c Threshold for Symptoms of Chronic Hyperglycemia?
Funding The study was supported by funds provided by the home institutions of the authors.![](https://www.thieme-connect.de/media/eced/202206/lookinside/thumbnails/01-2021-0031_10-1055-a-1493-0683-1.jpg)
Abstract
Aims of the study The minimum therapeutic goal regarding metabolic control for people with diabetes mellitus is the “absence of symptoms of hyperglycemia.” However, it is uncertain whether a level of HbA1c can be defined that guarantees the absence of these symptoms. The aim was to define an HbA1c threshold above which most patients show hyperglycemic symptoms.
Methods In a multicenter cross-sectional study, 137 patients with type 1 and 285 with type 2 diabetes were asked about their symptoms during periods of hyperglycemia with a standardized questionnaire. Seventeen symptoms of hyperglycemia were summarized to the total hyperglycemia symptom score (THSS; min. 0; max. 68). The answers could be given according to the frequency and intensity in the last 4 – 6 weeks.
Results The HbA1c threshold above which most patients showed hyperglycemic symptoms was 10.05% for patients with diabetes type 1 and 8.9%. for patients with type 2. Most confidence was reached on the symptoms of frequent urination” and “tiredness.” The mean THSS was 19.4 (±9.0) and showed a positive correlation with age (r=0.167; p<0.001) and HbA1c (r=0.254; p<0.001).
Conclusions We identified an HbA1c threshold above which most patients show symptoms of hyperglycemia. In the treatment of people with diabetes mellitus, a safety margin to this threshold should be maintained to preserve well-being and avoid distress. However, since hyperglycemia symptoms are subject to many influencing factors, an adjustment of the therapy—both intensification and de-intensification—should always be carried out in combination with the requested hyperglycemia symptoms and HbA1c value.
Publikationsverlauf
Eingereicht: 19. Januar 2021
Eingereicht: 16. März 2021
Angenommen: 13. April 2021
Artikel online veröffentlicht:
07. Juni 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 [Anonymous] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
- 2 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000; 321: 405-412
- 3 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-442 DOI: 10.1007/s00125-014-3460-0.
- 4 Bundesärztekammer (BÄK) KBK Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung In:. 2014
- 5 Canadian Diabetes Association Clinical Practice Guidelines Expert C Imran SA, Rabasa-Lhoret R. et al. Targets for glycemic control. Can J Diabetes 2013; 37: S31-S34 DOI: 10.1016/j.jcjd.2013.01.016.
- 6 Brown AF, Mangione CM, Saliba D. et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51: S265-S280 DOI: 10.1046/j.1532-5415.51.5s.1.x.
- 7 Muller N, Khunti K, Kuss O. et al. Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta diabetologica 2017; 54: 209-214 DOI: 10.1007/s00592-016-0939-9.
- 8 Muller N, Heller T, Freitag MH. et al. Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med. 2015 DOI: 10.1111/dme.12747
- 9 Lee SJ, Eng C. Goals of glycemic control in frail older patients with diabetes. J Am Med Assoc 2011; 305: 1350-1351 DOI: 10.1001/jama.2011.404
- 10 Vijan S, Sussman JB, Yudkin JS. et al. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014; 174: 1227-1234 DOI: 10.1001/jamainternmed.2014.2894.
- 11 Association AD. Standards of medical care in diabetes—2015. Diabetes Care 2015; 38: S1-S93
- 12 Bulpitt CJ, Shaw KM, Hodes C. et al. The symptom patterns of treated diabetic patients. Journal of chronic diseases 1976; 29: 571-583
- 13 Van der Does FE, De Neeling JN, Snoek FJ. et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996; 19: 204-210
- 14 Liu J, Li L, Deng K. et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. Brit Med J 2017; 357: j2499. DOI: 10.1136/bmj.j2499.
- 15 Kressin NR, Spiro A, Skinner KM. Negative affectivity and health-related quality of life. Med Care 2000; 38: 858-867
- 16 Zerssen D, Koeller DM, Rey ER. Die Befindlichkeitsskala (BS) – ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforsch 1970; 20: 915-918
- 17 Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Handbook of Psychology and Diabetes: A Guide to Psychological Measurements in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers; 1994
- 18 [Anonymous] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Eng J Med 1993; 329: 977-986 DOI: 10.1056/NEJM199309303291401.
- 19 Warren RE, Deary IJ, Frier BM. The symptoms of hyperglycaemia in people with insulin-treated diabetes: classification using principal components analysis. Diabetes Metab Res Rev 2003; 19: 408-414 DOI: 10.1002/dmrr.396
- 20 Sorkin DH, Billimek J, August KJ. et al. Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes. Fam Pract 2015; 32: 317-322 DOI: 10.1093/fampra/cmv014.
- 21 Bulpitt CJ, Palmer AJ, Battersby C. et al. Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care 1998; 21: 111-115
- 22 Ciechanowski PS, Katon WJ, Russo JE. et al. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 2003; 25: 246-252 DOI: 10.1016/s0163-8343(03)00055-0.
- 23 van Meijel LA, de Vegt F, Abbink EJ. et al. High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort. BMJ Open Diabetes Res Care 2020; 8. DOI: 10.1136/bmjdrc-2019-000935.
- 24 Geddes J, Schopman JE, Zammitt NN. et al. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008; 25: 501-504 DOI: 10.1111/j.1464-5491.2008.02413.x.